Xilio Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Xilio Therapeutics, Inc. (XLO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $39.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-03-01
- Xilio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- Xilio Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $39.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $39.00K 10-K · filed 2022-03-01 | |
| 2020-09-30 | $39.00K 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |